Sarilumab
 | Parts of this article (those related to lack of effectiveness against the Omicron variant) need to be updated. (January 2022) |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | IL-6R |
| Clinical data | |
| Trade names | Kevzara |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a617032 |
| License data | |
| Routes of administration | Subcutaneous |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 80% |
| Metabolism | likely proteases |
| Elimination half-life | 21 days (steady-state, estimated) |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6388H9918N1718O1998S44 |
| Molar mass | 144164.28 g·mol−1 |
  (what is this?) (verify) | |
Sarilumab, sold under the brand name Kevzara, is a human monoclonal antibody medication against the interleukin-6 receptor.[6] Regeneron Pharmaceuticals and Sanofi developed the drug for the treatment of rheumatoid arthritis (RA), for which it received US FDA approval on 22 May 2017 and European Medicines Agency approval on 23 June 2017.[7]
Development in ankylosing spondylitis has been suspended after the drug failed to show clinical benefit over methotrexate in a phase II trial.[8]
Medical uses
[edit]Sarilumab is used for the treatment of moderately to severely active rheumatoid arthritis in people who have not responded to, or did not tolerate, more conventional treatments.[9] It can be used alone or in combination with methotrexate or other disease-modifying antirheumatic drugs (DMARDs).[10][11]
Contraindications
[edit]In the European Union, sarilumab is contraindicated in people with active, severe infections.[10] While this is not listed as a contraindication under the US FDA approval, there is a boxed warning that recommends testing for hidden tuberculosis infection before treatment and monitoring for signs of an infection during therapy with sarilumab.[11]
Side effects
[edit]The MONARCH trial suggested a significantly higher incidence of neutropenia in patients receiving 200 mg sarilumab every 2 weeks, compared to patients being treated with adalimumab (13.6% vs 0.5%). However, infection rates were similar between both groups (28.8% vs 27.7%).[12]
Other common side effects that occurred in 1% to 10% of patients included thrombocytopenia (low platelet count), infections of the upper respiratory tract and the urinary tract, oral herpes, hyperlipidaemia, and injection site reactions such as pain or redness.[10]
Clinical trials
[edit]Rheumatoid arthritis
[edit]On 15 May 2013, both companies announced that 2 new trials were starting (COMPARE and ASCERTAIN) and the first patients had already been enrolled.[13]
In June 2015, a phase III trial (with methotrexate) for RA reported meeting its three coprimary endpoints.[14]
In November 2015, the SARIL-RA-TARGET trial reported good results (meeting both its coprimary end points).[15]
In November 2016, the MONARCH phase III trial comparing sarilimab to adalimumab (an anti-TNF) found sarilumab superior at reducing the DAS28-ESR score in patients with RA after 24 weeks.[12]
In July 2019, a multi-center trial was launched to study 'Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis.' [16]
History
[edit]In October 2016, the U.S. Food and Drug Administration (FDA) refused approval for marketing as a treatment for rheumatoid arthritis due to good manufacturing practice (GMP) violations.[12] The drug was eventually approved by the FDA on 22 May 2017.
Research
[edit]COVID-19
[edit]A study of 420 patients was halted in September 2020, due to lack of demonstrated effectiveness in treating COVID-19 symptoms.[17]
On 7 January 2021, following results from the REMAP-CAP trial, Tocilizumab and Sarilumab were added to the UK recommended list for COVID-19 treatment, the number needed to treat is 12, meaning for every 12 intensive care unit patients treated 1 additional person survives compared to treatment as normal, also speeding up patients' recovery and reducing the length of time that critically-ill patients need to spend in intensive care by about a week [18]
Tocilizumab seems to be more beneficial, whereas the clinical efficacy of Sarilumab has not been established as data on decreased mortality was often not significant. The number of trials did not allow for the identification of a specific patient subset that benefits the most from Sarilumab treatment, yet (May 2022).[19][20]
References
[edit]- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
- ^ "Arthritis". Health Canada. 8 May 2018. Retrieved 13 April 2024.
- ^ "Regulatory Decision Summary for Kevzara". Drug and Health Products Portal. 12 January 2017. Retrieved 13 April 2024.
- ^ "Kevzara- sarilumab injection, solution". DailyMed. 17 June 2024. Retrieved 26 August 2024.
- ^ "Kevzara EPAR". European Medicines Agency (EMA). 23 June 2017. Retrieved 26 August 2024.
- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Sarilumab" (PDF). ama-assn.org. American Medical Association.
- ^ "Kevzara: Authorisation details". European Medicines Agency. Archived from the original on 27 September 2017. Retrieved 28 September 2017.
- ^ "Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in Rheumatoid Arthritis". regeneron.com (Press release). Paris & Tarrytown, New York: Regeneron. 12 July 2011.
- ^ Boyce EG, Rogan EL, Vyas D, Prasad N, Mai Y (February 2018). "Sarilumab: Review of a Second IL-6 Receptor Antagonist Indicated for the Treatment of Rheumatoid Arthritis". Annals of Pharmacotherapy. 52 (8): 780–791. doi:10.1177/1060028018761599. PMID 29482351. S2CID 3580054.
- ^ a b c "Kevzara: EPAR – Product Information" (PDF). European Medicines Agency. 26 September 2017. Archived from the original (PDF) on 18 June 2018. Retrieved 29 November 2017.
- ^ a b Drugs.com: Sarilumab Monograph. Accessed 29 November 2017.
- ^ a b c Burmester GR, Lin Y, Patel R, van Adelsberg J, Mangan EK, Graham NM, et al. (May 2017). "Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial". Annals of the Rheumatic Diseases. 76 (5): 840–847. doi:10.1136/annrheumdis-2016-210310. PMC 5530335. PMID 27856432.
- ^ "Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA). May 2013" (PDF). Archived from the original (PDF) on 19 January 2017. Retrieved 15 May 2013.
- ^ Genovese MC, Fleischmann R, Kivitz AJ, Rell-Bakalarska M, Martincova R, Fiore S, et al. (June 2015). "Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study". Arthritis & Rheumatology. 67 (6): 1424–37. doi:10.1002/art.39093. PMID 25733246.
- ^ Walker T. "Sarilumab effective in broad range of RA patients: Study". Formulary Watch. Archived from the original on 21 November 2015.
{{cite web}}: CS1 maint: overridden setting (link) - ^ "More Information". Sarcoidosis Program. Archived from the original on 9 August 2019. Retrieved 9 August 2019.
- ^ Sanofi halts tests of arthritis drug for use as a COVID-19 treatment
- ^ Roberts M (7 January 2021). "Two more life-saving Covid drugs discovered". BBC News. Retrieved 7 January 2021.
- ^ - Yu SY, Koh DH, Choi M, et al. Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis. Emerg Microbes Infect. 2022;11(1):1154-1165. doi:10.1080/22221751.2022.2059405
- ^ - Sivapalasingam S, Lederer DJ, Bhore R, et al. Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19: A Randomized Clinical Trial [published online ahead of print, 2022 Feb 26]. Clin Infect Dis. 2022;ciac153. doi:10.1093/cid/ciac153
Further reading
[edit]- Bermejo I, Ren S, Simpson E, Clowes M, Scott DL, Young A, et al. (June 2018). "Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal" (PDF). PharmacoEconomics. 36 (12): 1427–1437. doi:10.1007/s40273-018-0677-7. PMID 29882210. S2CID 46969760.
- Genovese MC, van Adelsberg J, Fan C, Graham NM, van Hoogstraten H, Parrino J, et al. (August 2018). "Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes". Rheumatology. 57 (8): 1423–1431. doi:10.1093/rheumatology/key121. PMC 6055572. PMID 29746672.
- McCarty D, Robinson A (March 2018). "Efficacy and safety of sarilumab in patients with active rheumatoid arthritis". Therapeutic Advances in Musculoskeletal Disease. 10 (3): 61–67. doi:10.1177/1759720X17752037. PMC 5802641. PMID 29492111.
- Raimondo MG, Biggioggero M, Crotti C, Becciolini A, Favalli EG (2017). "Profile of sarilumab and its potential in the treatment of rheumatoid arthritis". Drug Design, Development and Therapy. 11: 1593–1603. doi:10.2147/DDDT.S100302. PMC 5447699. PMID 28579757.
